MARKET

CRIS

CRIS

Curis
NASDAQ
2.807
-0.033
-1.16%
Opening 12:52 03/14 EDT
OPEN
2.790
PREV CLOSE
2.840
HIGH
2.950
LOW
2.756
VOLUME
8.05K
TURNOVER
--
52 WEEK HIGH
17.49
52 WEEK LOW
2.570
MARKET CAP
23.77M
P/E (TTM)
-0.3595
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRIS last week (0303-0307)?
Weekly Report · 4d ago
Weekly Report: what happened at CRIS last week (0224-0228)?
Weekly Report · 03/03 12:20
Weekly Report: what happened at CRIS last week (0217-0221)?
Weekly Report · 02/24 12:21
Weekly Report: what happened at CRIS last week (0210-0214)?
Weekly Report · 02/17 12:17
Weekly Report: what happened at CRIS last week (0203-0207)?
Weekly Report · 02/10 12:08
Weekly Report: what happened at CRIS last week (0127-0131)?
Weekly Report · 02/03 12:15
Weekly Report: what happened at CRIS last week (0120-0124)?
Weekly Report · 01/27 12:19
Weekly Report: what happened at CRIS last week (0113-0117)?
Weekly Report · 01/20 12:07
More
About CRIS
More
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Recently
Symbol
Price
%Change

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.